bioSyntagma logo

bioSyntagma

Eliminating trial-and-error cancer treatments through biomarker discovery and predictive analytics

2 employees · est. 2015 · Phoenix, United States

VS
BostonGene logo

BostonGene

Transforming Cancer Care: From Treating a Diagnosis to Treating the Person

436 employees · est. 2015 · Waltham, United States

BostonGene is the larger of the two.

Side-by-Side Comparison

bioSyntagma BostonGene
Founded
2015 2015
Headquarters
Phoenix, United States Waltham, United States
Employees
2 436 larger
Industry
Biotechnology, Life Sciences Analytics, Health Care, Clean Energy
Funding Stage
Grant Series B
Total Funding
$1.38M $200.00M
Funding Rounds
4 2
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Not tracked yet Precision Medicine, Cancer Care, Biomarker Discovery, AI-Integrated Analytics, Personalized Therapy, Immunooncology, Bioinformatics, Genomics, Medical Technology, Therapeutic Decision-Making, Concierge-Service Model
Website
biosyntagma.com bostongene.com
bioSyntagma logo

About bioSyntagma

bioSyntagma is a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. The company’s Molecular Fingerprint™ (mPrint™) platform creates a comprehensive, multi-omic and spatial profile of tissue to get a complete an...

BostonGene logo

About BostonGene

BostonGene is a transformative startup with a slogan of "Transforming Cancer Care: From Treating a Diagnosis to Treating the Person." Founded in 2015 and based in the United States, the company is focused on providing AI-integrated molecular analytics and biomarker discovery for precision matching o...

We will tell you when either one moves

BounceWatch watches bioSyntagma and BostonGene for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at bioSyntagma and BostonGene — by email.

Frequently Asked Questions

bioSyntagma — Eliminating trial-and-error cancer treatments through biomarker discovery and predictive analytics. BostonGene — Transforming Cancer Care: From Treating a Diagnosis to Treating the Person. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
bioSyntagma has raised $1.38M while BostonGene has raised $200.00M.
bioSyntagma and BostonGene operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare bioSyntagma with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at bioSyntagma on 13 Sep 2024, and BostonGene on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy